There are several key genes recurrently mutated in lung cancer. Genomic DNA is isolated from formalin fixed paraffin embedded tissue and the DNA sequence of targeted regions of the ALK, BRAF, CD274, EGFR, ERBB2, KRAS, and MET genes is determined using next-generation sequencing (NGS) technology.

The Therascreen® KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Roto-Gene® Q MDx instrument for the detection of seven somatic mutations in codons 12 and 13 (exon 2) of the human KRAS oncogene, using DNA extracted from formalin-fixed, paraffin-embedded (FFPE) tissue.

There are key genes recurrently mutated in colorectal cancer. Genomic DNA is isolated from formalin fixed paraffin embedded tissue and the DNA sequence of targeted regions of the BRAF, KRAS, and NRAS genes is determined using next-generation sequencing (NGS) technology.

Polymerase chain reaction (PCR) allows discrimination of individual members of the sufficiently diverse TCR-gamma gene family. By using PCR amplification of the TCR-gamma gene, a dominant clone can be identified in the majority of T-cell neoplasms.

Polymerase chain reaction (PCR) allows discrimination of individual members of the sufficiently diverse TCR-beta gene family. By using PCR amplification of the TCR-beta gene, a dominant clone can be identified in the majority of T-cell neoplasms.

Reverse transcriptase polymerase chain reaction (RT-PCR) for quantitative detection of t(15;17) PML-RARA, a recurrent genetic abnormality found in acute promyelocytic leukemia (APL). This RNA-based test detects all three gene fusion patterns: type A (short, S-form, bcr-3), type B (long, L-form, bcr-1), and type B variant (variable, V-form, bcr-2).

Detection of mutations in key genes recurrently mutated in myeloid malignancies. Genomic DNA is isolated from bone marrow aspirates or peripheral blood and the DNA sequence of targeted regions of the ASXL1, BCOR, BRAF, CALR, CBL, CEBPA, CSF3R, DDX41, DNMT3A, ETNK1, ETV6, EZH2, GATA2, GNAS, GNB1, IDH1, IDH2, JAK2, KIT, KRAS, MPL, NF1, NPM1, NRAS, PDGFRA, PHF6, PPM1D, PTPN11, RAD21, RUNX1, SETBP1, SF3B1, SH2B3, SMC1A, SMC3, SRSF2, STAG2, STAT3, STAT5B, TET2, TP53, U2AF1, WT1, ZRSR2 genes is determined using next-generation sequencing (NGS) technology.

Detects mutations in key genes recurrently mutated in myeloproliferative neoplasms (MPN). DNA sequence of targeted regions of the CALR, CSF3R, JAK2, MPL and SETBP1 genes is determined using next generation sequencing technology.

Detects MPL mutations, which are found in a subset of myeloproliferative neoplasms (MPN). DNA sequence of exon 10 including W515L/K and S505 is determined using next-generation sequencing (NGS) technology.

Detects the MLL partial tandem duplication (PTD) between exons 2 and 8 in the MLL gene.